Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Vergelijkende studie van EnliTuo® voor en na technologische verandering bij gezonde mannelijke vrijwilligers

29 september 2026 bijgewerkt door: Taizhou Mabtech Pharmaceutical Co.,Ltd

Gerandomiseerde, dubbelblinde, parallel-gecontroleerde, enkelvoudige dosis farmacokinetische, veiligheids- en immunogeniciteit vergelijkende studie van EnliTuo® vóór en na technologische verandering bij gezonde mannelijke vrijwilligers

This study is a randomized, double-Blind, parallel-controlled, single-dose pharmacokinetic, safety, and immunogenicity comparative study of EnliTuo® before and after technology change in healthy male volunteers.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Werkelijk)

86

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Shanghai, China
        • Shanghai Xuhui Central Hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 45 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Mannelijk

Beschrijving

Inclusion Criteria:

  • Healthy males aged ≥ 18 years and ≤ 45 years on the day of signing the informed consent form;
  • At screening, body weight ≥ 50 kg and ≤ 80 kg, with a Body Mass Index (BMI) between 19.0 and 26.0 kg/m² (inclusive of boundary values);
  • Capable of understanding the study, including its purpose, research procedures, potential risks, etc., and able to communicate well with researchers and complete the study in accordance with the study requirements;
  • Voluntarily sign the informed consent form.

Exclusion Criteria:

  • Subjects with any abnormally clinically significant findings in comprehensive examinations (vital signs, physical examination, electrocardiogram, chest X-ray, abdominal ultrasound, blood routine, urine routine, blood biochemistry, coagulation, etc.) as judged by the investigator;
  • Subjects with a history of major diseases in the cardiovascular, endocrine, nervous, digestive, respiratory, genitourinary, hematological, immune, or mental systems, or currently suffering from any disease in the above systems;
  • Subjects with a known or suspected history of keratitis, ulcerative keratitis, conjunctivitis, blepharitis, or severe dry eye;
  • Subjects with hereditary bleeding tendency, coagulation dysfunction, or a history of thrombotic or hemorrhagic diseases;
  • Subjects with active infections requiring systemic treatment;
  • Subjects positive for any of HBV surface antigen, HCV antibody, HIV antibody, or Treponema pallidum antibody;
  • Subjects with a history of malignant tumors within the past 5 years, except for completely resected in-situ cutaneous basal cell carcinoma or squamous cell carcinoma;
  • Subjects who have undergone surgical operations within 4 weeks before screening, or plan to undergo surgery during the trial period;
  • Subjects who have used any prescription drugs, over-the-counter drugs, traditional Chinese medicines, proprietary Chinese medicines, health supplements, etc., within 4 weeks before screening, or whose use of the above substances has not exceeded 5 half-lives (whichever is longer);
  • Subjects who have used any biological products or received any vaccines within 12 weeks before screening, or plan to receive any vaccines during the study period;
  • Subjects currently enrolled in other clinical studies of drugs or medical devices, or whose time since the end of the last enrolled clinical study is less than 12 weeks, or whose time since the last trial drug administration has not exceeded 5 half-lives (whichever is longer);
  • Subjects positive for anti-drug antibodies against anti-epidermal growth factor receptor antibodies;
  • Subjects with substance abuse, or who have used soft drugs within 3 months before screening or hard drugs within 1 year before screening; or who consume excessive tea, coffee, and/or caffeinated beverages daily (more than 8 cups, 1 cup = 250 mL); or who have a positive urine drug screen;
  • Subjects with alcoholism, or whose weekly alcohol consumption exceeds 14 units within 3 months before screening (1 unit = 17.7 mL ethanol, i.e., 1 unit = 357 mL of beer with 5% alcohol content, 43 mL of liquor with 40% alcohol content, or 147 mL of wine with 12% alcohol content); or who have a positive alcohol breath test; and those who cannot cooperate with alcohol prohibition during the study;
  • Subjects who smoked more than 10 cigarettes per day on average within 6 months before screening;
  • Subjects who engaged in strenuous activities within 72 hours before drug administration, or cannot avoid strenuous activities during the study; or have other physiological or pathological conditions that may affect the absorption, distribution, metabolism, or excretion of the study drug;
  • Subjects who have donated blood (including component blood) or lost more than 400 mL of blood, or received blood transfusions within 3 months before screening; or donated blood (including component blood) or lost more than 200 mL of blood within 1 month before screening;
  • Subjects with a known history of allergy to the active ingredient or any excipient of the study drug, or to other biological products; or with a history of atopic allergic diseases (e.g., asthma, urticaria, eczematous dermatitis, etc.); or with allergic diathesis;
  • Subjects who cannot tolerate venipuncture or have a history of fainting due to needle or blood;
  • Subjects with special dietary requirements who cannot accept the diet provided by the clinical trial center;
  • Subjects who cannot take effective contraceptive measures or plan to donate sperm within 3 months after the administration of the study drug;
  • Other conditions deemed by the investigator to make the subject unsuitable for participating in this study.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: New technology Enlituo

treated with new technology Enlituo through single intravenous drip

250 mg/m^2, single intravenous drip

Actieve vergelijker: Approved technology Enlituo

treated with Approved technology Enlituo through single intravenous drip

250 mg/m^2, single intravenous drip

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
AUC0-∞
Tijdsspanne: From enrollment to the end of treatment at 28 days

Area under the concentration time curve extrapolated to infinity

From enrollment to the end of treatment at 28 days

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
AUC0-t
Tijdsspanne: From enrollment to the end of treatment at 28 days

Area under the concentration time curve from time zero to the last measurable time point.

From enrollment to the end of treatment at 28 days
Cmax
Tijdsspanne: From enrollment to the end of treatment at 28 days

Peak concentration.

From enrollment to the end of treatment at 28 days
Tmax
Tijdsspanne: From enrollment to the end of treatment at 28 days

time to peak

From enrollment to the end of treatment at 28 days
t1/2
Tijdsspanne: From enrollment to the end of treatment at 28 days

half-life

From enrollment to the end of treatment at 28 days
λz
Tijdsspanne: From enrollment to the end of treatment at 28 days

Terminal Elimination Rate Constant

From enrollment to the end of treatment at 28 days
CL
Tijdsspanne: From enrollment to the end of treatment at 28 days

clearance

From enrollment to the end of treatment at 28 days
Vd
Tijdsspanne: From enrollment to the end of treatment at 28 days

volume of distribution

From enrollment to the end of treatment at 28 days
Immunogenicity
Tijdsspanne: From enrollment to the end of treatment at 28 days

Anti-drug antibody positive rate

From enrollment to the end of treatment at 28 days
Adverse Event
Tijdsspanne: From enrollment to the end of treatment at 6 months

Incidence and Severity of Adverse Events

From enrollment to the end of treatment at 6 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Jingying Jia, PhD, Xuhui Central Hospital, Shanghai

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

11 november 2025

Primaire voltooiing (Werkelijk)

14 april 2026

Studie voltooiing (Werkelijk)

14 april 2026

Studieregistratiedata

Eerst ingediend

17 november 2025

Eerst ingediend dat voldeed aan de QC-criteria

17 november 2025

Eerst geplaatst (Werkelijk)

24 november 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

30 september 2026

Laatste update ingediend die voldeed aan QC-criteria

29 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Andere studie-ID-nummers

  • CMAB009-C-102

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

After the study result is published, email the application registration contact or the study leader to obtain it.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren